GYRE

Gyre TherapeuticsA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$11.50

+106.8% vs current

Most likely

Base case

55%

Probability

Target price

$6.00

+7.9% vs current

B-

Bear case

25%

Probability

Target price

$3.75

-32.6% vs current

AI sentiment snapshot

Latest data as of 2026-05-29

AI commentary

Coverage remains filing-driven: the packet has no recent news items and no analyst revision data, so conviction stays low despite the useful primary-source updates. The Q1 2026 10-Q showed modest revenue growth, continued ETUARY concentration, the May 2026 Cullgen acquisition, and ongoing Hydronidone optionality, which supports a monitoring stance rather than a thesis-reset. The analyst target median is directionally bullish, but the sample size is unavailable and should not be treated as strong consensus evidence.

RankAlpha Sentiment Codex - 2026-05-29

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-04eventCullgen broadens the pipeline, but integration and capital allocation are now centralMedium impact

Gyre completed the all-stock Cullgen acquisition in May 2026 and said it is evaluating pipeline and clinical-development strategy to optimize capital allocation and prioritize programs, so the deal adds breadth while also raising execution and integration risk. [#10-Q-2026-05-08]

2026-05-08catalystQ1 2026 results were modestly better, but the commercial mix stayed narrowMedium impact

Revenue rose to $22.5m from $22.1m and consolidated net income was $2.9m versus $0.8m a year ago, but ETUARY still accounted for about 93.1% of product revenue and sales remain concentrated through PRC distributors, so the quarter is incremental rather than thesis-changing. [#10-Q-2026-05-08]

2026-06-30eventHydronidone's China NDA and priority review remain the nearest rerating catalystHigh impact

The CDE granted priority review and Gyre Pharmaceuticals submitted the NDA on March 22, 2026, keeping the next monitor on regulatory progress for Hydronidone in China rather than on a new operating beat. [#10-Q-2026-05-08]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-29 • Updated nightlySource: Internal modelMethodology